These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

48 related items for PubMed ID: 2631477

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
    Rohatagi S, Shah B, Zhang J, Zeng Z, Kirkesseli S, Jensen BK.
    J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741
    [Abstract] [Full Text] [Related]

  • 5. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
    Fagerholm U, Breuer O, Swedmark S, Hoogstraate J.
    J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of the enantiomers of gallopamil.
    Gross AS, Mikus G, Ratge D, Wisser H, Eichelbaum M.
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1102-12. PubMed ID: 9190842
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
    Dow J, Dulery BD, Hornsperger JM, Di Francesco GF, Keshary P, Haegele KD.
    Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.
    Gupta SK, Sathyan G.
    J Clin Pharmacol; 1999 Mar; 39(3):289-96. PubMed ID: 10073329
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M, Retzow A, Vens-Cappell B.
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of oral sustained release clonidine in humans.
    MacGregor TR, Relihan GL, Keirns JJ.
    Arzneimittelforschung; 1985 Feb; 35(1A):440-6. PubMed ID: 4039184
    [Abstract] [Full Text] [Related]

  • 16. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
    Yang XG, Nie SF, Bai HJ, Zhang GJ, Pan WS.
    Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
    Ericsson H, Hamrén B, Bergstrand S, Elebring M, Fryklund L, Heijer M, Ohman KP.
    Drug Metab Dispos; 2004 Sep; 32(9):923-9. PubMed ID: 15319332
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.